{"commentary":{"count":19,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":9,"youtube":7,"podcast":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03794544\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT03794544","nct_id":"NCT03794544","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03794544. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive durvalumab 1500 mg intravenously (IV) every 4 weeks (Q4W; on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).","label":"Durvalumab 1500 mg","type":"EXPERIMENTAL"},{"description":"Participants will receive durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and oleclumab 3000 mg IV every 2 weeks (Q2W; on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).","label":"Durvalumab 1500 mg + Oleclumab 3000 mg","type":"EXPERIMENTAL"},{"description":"Participants will receive durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and monalizumab 750 mg IV Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).","label":"Durvalumab 1500 mg + Monalizumab 750 mg","type":"EXPERIMENTAL"},{"description":"Participants will receive danvatirsen 200 mg IV on Days 1, 3, and 5 of Week 0 (7-day danvatirsen lead-in period), followed by durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and danvatirsen 200 mg IV every week (on Week 1 Day 1, Week 2 Day 1, Week 3 Day 1, and Week 4 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).","label":"Durvalumab 1500 mg + Danvatirsen 200 mg","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2021-01-13","type":"ACTUAL"},"conditions":["Resectable","Early-stage","NSCLC"],"enrollment":{"count":84,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Durvalumab","type":"DRUG"},{"name":"Oleclumab","type":"COMBINATION_PRODUCT"},{"name":"Monalizumab","type":"COMBINATION_PRODUCT"},{"name":"Danvatirsen","type":"COMBINATION_PRODUCT"}],"last_update":"2022-02-24","lead_sponsor":"MedImmune LLC","official_title":"A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Subjects With Resectable, Early-stage (I [> 2 cm] to IIIA) Non-small Cell Lung Cancer (NeoCOAST)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-01-13","type":"ACTUAL"},"primary_outcomes":[{"measure":"Major Pathological Response Rate","timeFrame":"Day 1 through Day 42"}],"references":[{"citation":"Cascone T, Kar G, Spicer JD, Garcia-Campelo R, Weder W, Daniel DB, Spigel DR, Hussein M, Mazieres J, Oliveira J, Yau EH, Spira AI, Anagnostou V, Mager R, Hamid O, Cheng LY, Zheng Y, Blando J, Tan TH, Surace M, Rodriguez-Canales J, Gopalakrishnan V, Sellman BR, Grenga I, Soo-Hoo Y, Kumar R, McGrath L, Forde PM. Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial. Cancer Discov. 2023 Nov 1;13(11):2394-2411. doi: 10.1158/2159-8290.CD-23-0436.","pmid":"37707791","type":"DERIVED"}],"start_date":{"date":"2019-03-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT03794544"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03794544"}